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Abstract
Purpose Long-term persistence with pharmacotherapy for
overactive bladder (OAB) requires a drug with an early onset
of action and good efficacy and tolerability profile. Although
antimuscarinics improve OAB symptoms within 1–2 weeks
of initiating treatment, adherence after 3 months is relatively
poor due to bothersome side effects (e.g., dry mouth and
constipation). Mirabegron, a b3-adrenoceptor agonist, has
demonstrated significant improvements in key symptoms of
OAB and good tolerability after 12 weeks in Phase III studies.
Methods This was a prespecified pooled analysis of three
randomized, double-blind, placebo-controlled, 12-week
studies, and a Phase II study, to evaluate efficacy and tol-
erability of mirabegron 25 and 50 mg versus placebo. The
main efficacy endpoints were change from baseline to
week 1 (Phase II only), week 4, and final visit in mean
number of incontinence episodes/24 h, micturitions/24 h,
and mean volume voided/micturition (MVV).
Results A significant benefit for mirabegron 25 and 50 mg
versus placebo was evident at the first assessment point,
4 weeks after initiation of therapy, in Phase III studies for
incontinence, micturitions, and MVV. The earliest measured
benefit was after 1 week, in the Phase II study. Quality-of-life
parameters also significantly improved with mirabegron 25
and 50 mg as early as week 4. Significant benefits continued
throughout the studies. Mirabegron was well tolerated.
Conclusions The early onset of action and good overall
efficacy and tolerability balance that mirabegron offers
may lead to high rates of persistence with mirabegron in
the long-term treatment of OAB.
Keywords Mirabegron  Overactive bladder 
b3-Adrenoceptor agonist  Onset of action
Introduction
Overactive bladder (OAB) affects 12–16 % of adults
across Europe, North America, and Japan [1–4]. Its prev-
alence increases with age, affecting *30 % of individuals
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[65 years. Chronic, bothersome OAB-associated symp-
toms significantly impact quality of life (QOL) [5, 6] and
increase the likelihood of sleep deprivation, depression [7,
8], falls, and fractures [9].
Successful therapy and patient persistence are dependent
on early onset of action and low incidence of side effects;
therefore, it is important to determine the earliest time at
which a therapy shows efficacy and to evaluate adverse
events (AEs). Many medications have demonstrated effi-
cacy in reducing OAB symptoms, but efficacy endpoints in
OAB studies are evaluated at set timepoints after treatment
initiation, with 4 weeks often the earliest assessment.
Oral antimuscarinic drugs, the current mainstay for
OAB treatment, are associated with improvements in
urgency and frequency as early as 1 week after initiating
treatment [10–14]; however, there is heterogeneity among
antimuscarinics with respect to onset and duration of
action. Furthermore, some patients do not respond ade-
quately to antimuscarinics [15], and/or experience intoler-
able AEs (e.g., dry mouth, constipation, and blurred vision)
due to non-selective anticholinergic effects [16]. Such
patients either persist with unsatisfactory treatment or
discontinue therapy. Consequently, antimuscarinics are
often associated with poor levels of treatment adherence in
patients suffering from OAB [17].
Clinicians who treat OAB generally evaluate patients
4 weeks post-initiation of therapy, in order to ascertain
where there is inadequate efficacy and the need for dose
escalation [18]. Early resolution of symptoms may help
improve adherence and avoid use of higher doses of an-
timuscarinics, with its associated increased risk of AEs.
Mirabegron, a b3-adrenoceptor agonist, is approved for
OAB treatment in Japan, the USA, Canada, and the
European Union and represents the first in a new class of
drugs with a mechanism of action distinct from antimu-
scarinics [19, 20]. Labeling differs between countries, with
a recommended starting dose of 25 mg once-daily (QD) in
the USA and Canada, with an option to increase to 50 mg
QD, and recommended doses of 50 mg QD in Japan and
Europe, with the 25 mg dose reserved for special popula-
tions (e.g., those with severe renal impairment or moderate
hepatic impairment). Efficacy and safety of mirabegron
have been investigated in three large 12-week international
Phase III studies [21–23]. Significant improvements in key
symptoms of OAB: urgency, frequency, and incontinence,
were evident after 12 weeks.
Methods
This was a prespecified pooled analysis of three randomized,
double-blind, placebo-controlled, 12-week studies, evalu-
ating efficacy and tolerability of mirabegron 25, 50, and
100 mg (study 178-CL-046 [NCT00689104] [21], study
178-CL-047 [NCT00662909] [22], study 178-CL-074
[NCT00912964]) [23]. Data from a European Phase II study
(study 178-CL-044 [NCT00337090]) [20] in which patients
received mirabegron 25, 50, 100, and 200 mg were also
examined to establish the onset of action of mirabegron. Data
for unlicensed doses (100 and 200 mg) are not presented.
All studies were conducted in accordance with ethical
principles derived from the Declaration of Helsinki, Good
Clinical Practice, and International Conference of Harmo-
nization Guidelines. All patients provided written informed
consent.
The studies shared similar designs and enrolled males
and females C18 years with symptoms of OAB for
C3 months. Following a 2-week placebo run-in period to
establish baseline urinary values and eligibility, patients
were randomized if, during a 3-day micturition diary per-
iod, they recorded C8 micturitions/24 h and C3 urgency
episodes (based on urgency grade 3 or 4 using Patient
Perception of Intensity of Urgency Scale) with/without
urgency incontinence. Patients were randomized equally to
receive the following oral once-daily treatments for
12 weeks:
• Study 178-CL-044 placebo, mirabegron 25, 50, 100,
200 mg, tolterodine ER 4 mg
• Study 178-CL-046 placebo, mirabegron 50, 100 mg,
tolterodine ER 4 mg
• Study 178-CL-047 placebo, mirabegron 50, 100 mg
• Study 178-CL-074 placebo, mirabegron 25, 50 mg.
Efficacy measures were recorded in a patient micturition
diary over 3 days prior to clinic visits: at baseline and week
1 (Phase II study only), weeks 4, 8, 12, and final visit (end
of treatment, i.e., last on-treatment assessment including
patients not completing week 12 visit).
The main efficacy endpoints in this analysis were
change from baseline to week 1 (Phase II only), week 4,
and final visit in mean number of incontinence episodes/
24 h, micturitions/24 h, and mean volume voided/micturi-
tion. Additional efficacy endpoints were changes in mean
numbers of urgency episodes (grades 3 or 4)/24 h, urgency
incontinence episodes/24 h, mean level of urgency, QOL
scores on the International Consultation on Incontinence
Questionnaire-Overactive Bladder (ICIQ-OAB) and ICIQ-
OABqol for the Phase II study; and change in Overactive
Bladder Questionnaire (OAB-q) scores for Phase III stud-
ies. Tolerability was assessed according to discontinuation
rates and reasons for discontinuation.
The safety analysis set (SAF) comprised all randomized
patients who took C1 dose of double-blind study drug; the
full analysis set (FAS) comprised SAF patients who had
C1 micturition measurement at baseline and C1 post-base-
line micturition measurement; the FAS-incontinence (FAS-
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I) set comprised FAS patients who reported C1 incontinence
episode at baseline. Efficacy analyses were performed using
the FAS except for incontinence episode endpoints, which
used the FAS-I. Safety analyses were performed using the
SAF.
Analysis of covariance (ANCOVA) was performed on
the 178-CL-044 population (with treatment group and
country as fixed factors and baseline as a covariate), the
pooled population (treatment group, sex, and study as
fixed factors and baseline as a covariate) and the 178-CL-
074 population (treatment group, sex, and geographical
region as fixed factors, baseline as a covariate). For
incontinence and urgency incontinence endpoints in the
pooled population and 178-CL-074, stratified rank
ANCOVA was used for hypothesis testing. All other
hypothesis testing was performed using ANCOVA. Based
on the ANCOVA, least squares (LS) mean estimates for
mean changes from baseline within treatment groups and
differences between each mirabegron treatment group and
placebo were derived.
Results
Patient demographics and baseline characteristics
Patient demographics and baseline characteristics were
comparable across studies and treatment groups (Table 1).
Most patients were female (*70 % in the Phase III studies,
*90 % in the Phase II study).
Efficacy: Study 178-CL-044
In this study, which was powered to detect dose response,
mirabegron 25 and 50 mg demonstrated improvement over
placebo as early as the first measured timepoint of week 1
(Fig. 1). Specifically, there were statistically significant
reductions in incontinence episodes/24 h versus placebo
for mirabegron 50 mg at week 1. In addition, at week 4,
mirabegron 25 and 50 mg were associated with statistically
significant reductions versus placebo in micturitions/24 h
and volume voided/24 h.
Table 1 Patient demographics and baseline characteristics
Study 178-CL-044 (FAS) Study 178-CL-074 (FAS) Pooled Phase III studies (FAS)
Placebo
(n = 166)
Mirabegron Placebo
(n = 415)
Mirabegron
25 mg (n = 410)
Placebo
(n = 1,328)
Mirabegron
50 mg (n = 1,324)
25 mg
(n = 167)
50 mg
(n = 167)
Gender (n, %)
Male 15 (9.0) 20 (12.0) 18 (10.8) 127 (30.6) 134 (32.7) 362 (27.3) 382 (28.9)
Female 151 (91.0) 147 (88.0) 149 (89.2) 288 (69.4) 276 (67.3) 966 (72.7) 942 (71.1)
Age (years)
Mean (SD) 57.1 (12.9) 57.2 (12.1) 56.9 (12.5) 58.2 (13.8) 58.8 (12.7) 59.2 (13.2) 59.7 (12.6)
Range 21–80 20–78 26–84 22–85 22–85 20–95 21–91
Race n (%)
White 166 (100) 162 (97.0) 162 (97.0) 372 (89.6) 373 (91.0) 1,227 (92.4) 1,235 (93.3)
Black or African-American 0 2 (1.2) 0 34 (8.2) 31 (7.6) 80 (6.0) 61 (4.6)
Asian 0 1 (0.6) 0 7 (1.7) 5 (1.2) 13 (1.0) 17 (1.3)
Other 0 1 (0.6) 3 (1.8) 2 (0.5) 1 (0.2) 8 (0.6) 11 (0.8)
Missing 0 1 (0.6) 2 (1.2) 0 0 0
Height (cm), n (SD) 164.5 (7.1) 165.2 (7.7) 164.7 (8.2) 166.9 (9.1) 166.8 (9.3) 166.3 (8.9) 166.4 (9.2)
Weight (kg), n (SD) 75.1 (14.3) 75.8 (13.2) 72.9 (13.2) 81.0 (18.8) 82.4 (19.0) 80.4 (18.4)a 80.3 (18.3)
Type of OAB, n (%)
Urgency incontinence 74 (44.6) 79 (47.3) 67 (40.1) 117 (28.2) 156 (38.0) 442 (33.3) 491 (37.1)
Mixed 52 (31.3) 41 (24.6) 47 (28.1) 137 (33.0) 124 (30.2) 415 (31.3) 412 (31.1)
Frequency 40 (24.1) 47 (28.1) 53 (31.7) 161 (38.8) 130 (31.7) 471 (35.5) 421 (31.8)
Duration of OAB symptoms (months) n = 63b n = 63b n = 53b
Mean (SD) 54.2 (66.9) 48.0 (35.7) 45.1 (53.7) 91.4 (96.1) 97.4 (115.1) 86.3 (99.1) 85.2 (93.1)
Previous OAB drug, n (%)
Yes 71 (42.8) 82 (49.1) 77 (46.1) 217 (52.3) 219 (53.4) 704 (53.0) 688 (52.0)
a Missing weight for 1 (0.1 %) of subjects in the placebo group
b If the day and month were missing or the date was completely missing for the start of OAB symptoms, duration of OAB symptoms was not calculated
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Improvement continued throughout the study, with statis-
tically significant differences versus placebo at final visit for
mirabegron 25 and 50 mg for incontinence episodes/24 h, and
for mirabegron 50 mg for micturitions/24 h and volume
voided/24 h. For the additional endpoints, mirabegron 25 and
50 mg showed improvements versus placebo at all timepoints
for urgency episodes (grade 3 or 4)/24 h, urgency inconti-
nence episodes/24 h and level of urgency. These improve-
ments were statistically significant for mirabegron 25 and
50 mg versus placebo at final visit for urgency incontinence
episodes/24 h and for mirabegron 25 mg for urgency episodes
(grade 3 or 4).
In terms of QOL, mirabegron 25 and 50 mg showed
improvements versus placebo at all timepoints for ICIQ-
OAB and ICIQ-OABqol (except for 25 mg at week 1).
Efficacy: study 178-CL-074: 25 mg mirabegron group
Mirabegron 25 mg demonstrated statistically significant
reductions from baseline to final visit versus placebo in
mean number of incontinence episodes/24 h and mictu-
ritions/24 h. Numerical improvements (not statistically
significant) were seen at the earliest measured timepoint
(week 4) for the key symptoms of OAB (mean number of
incontinence episodes/24 h, micturitions/24 h, and mean
volume voided/micturition). Improvements continued
over the study period. Numerically greater improvements
versus placebo were also seen for mirabegron 25 mg at
week 4 on the 3 urgency assessments (mean level of
urgency, mean number of urgency incontinence episodes/
24 h and urgency episodes/24 h [grades 3 or 4]) and on all
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Fig. 1 Mean change from baseline at each visit in Study 178-CL-
044: a the number of incontinence episodes/24 h (full analysis set-
incontinence), b number of number of micturitions/24 h (full analysis
set), and c volume voided/micturition (full analysis set). *Statistically
significant treatment benefit relative to placebo without multiplicity
adjustment (P \ 0.05). BL baseline, FAS full analysis set, FAS-I full
analysis set-incontinence
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OAB-q scales and subscales. These improvements were
statistically significant versus placebo for the HRQL total
score and the Coping and Concern subscale scores.
Efficacy: pooled analysis: 50 mg mirabegron group
Mirabegron 50 mg demonstrated statistically significantly
greater reductions from baseline to earliest measured
assessment (week 4) and to final visit versus placebo for
incontinence episodes/24 h, micturitions/24 h, and mean
volume voided/micturition. Effectiveness was maintained
throughout the treatment period (Fig. 2). Statistically sig-
nificant differences versus placebo were also seen for mira-
begron 50 mg at week 4 and final visit in mean number of
urgency episodes (grades 3 or 4), urgency incontinence
episodes/24 h, OAB-q Symptom Bother, HRQL total, and
the Coping and Concern subscales.
Safety
The overall incidence of TEAEs was similar across treat-
ment groups in all studies (Table 2), and there was no
evidence of a dose–response relationship across mirabeg-
ron treatment groups for overall rates of TEAEs. The most
common TEAEs (in C3 % of the total mirabegron group)
were headache, hypertension, nasopharyngitis, and urinary
tract infection. The most common drug-related TEAEs
were hypertension, headache, and dry mouth. The majority
of AEs were of mild or moderate severity.
Discussion
OAB is a chronic symptom complex and successful man-
agement requires early onset of action of pharmacotherapy
plus a good tolerability profile with minimal levels of
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Fig. 2 Mean change from baseline (±SE) at each visit in the pooled
Phase III studies: a the number of incontinence episodes/24 h (full
analysis set-incontinence), b number of number of micturitions/24 h
(full analysis set), and c volume voided/micturition (full analysis set).
#Statistically significant treatment benefit relative to placebo
(P \ 0.05) with multiplicity adjustment. *Statistically significant
treatment benefit relative to placebo (P \ 0.05) without multiplicity
adjustment. SE standard error, FAS full analysis set
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bothersome side effects in order to encourage long-term
persistence with treatment. Although evidence suggests that
antimuscarinics improve OAB symptoms within 1–2 weeks
of initiating treatment, adherence after 3 months and 1 year
is relatively poor due to the often intolerable non-selective
anticholinergic effects [17].
These results from a large OAB patient population indicate
that mirabegron 25 and 50 mg provide an early onset of action
comparable to that demonstrated in previous antimuscarinic
studies. A significant benefit was evident at the first assess-
ment after initiation of therapy (4 weeks) in Phase III studies
for incontinence, micturitions, and mean volume voided/
micturition. However, the earliest measured onset of benefit
was at 1 week, as demonstrated in a Phase II study. QOL
parameters also significantly improved with mirabegron 25
and 50 mg, as early as week 4, suggesting that these
improvements are likely to translate into clinically meaningful
benefits. Significant benefits were maintained throughout the
treatment period in all studies.
As with most medications, some patients experience
symptom improvements rapidly while others require several
weeks to experience meaningful improvements. This delay
to maximum effect may be because it takes time for patients
to modify coping behaviors (e.g., timed voiding, voiding at
first sensation of urgency) that they use to control urgency
and urge incontinence [24, 25], and it can take several weeks
for patients to rely on medication and the relief provided.
Clinicians need to inform patients about onset of action to
manage expectations regarding time to clinical benefit.
Tolerability is another important determinant of persis-
tence; with mirabegron, this was shown to be comparable
with placebo in the pooled Phase III analysis and the Phase
II study. In addition, rates of discontinuation due to TEAEs
with mirabegron 25 and 50 mg were low and comparable
with placebo.
Limitations with the present study relate to the lack of
pooled data for the 25 mg dose, with data only available
from a single Phase III study. The evaluation of mirabegron
Table 2 Overview of treatment-emergent adverse events (SAF)
Number of subjects (%) Study 178-CL-044 (SAF) Study 178-CL-074
(SAF)
Pooled Phase III studies
(SAF)
Placebo Mirabegron Placebo
(n = 433)
Mirabegron
25 mg
(n = 432)
Placebo
(n = 1,380)
Mirabegron
50 mg
(n = 1,375)(n = 169) 25 mg
(n = 169)
50 mg
(n = 169)
Any TEAE 73 (43.2) 74 (43.8) 74 (43.8) 217 (50.1) 210 (48.6) 658 (47.7) 647 (47.1)
Drug-related TEAE 26 (15.4) 34 (20.1) 38 (22.5) 77 (17.8) 87 (20.1) 232 (16.8) 256 (18.6)
TEAE leading to discontinuation 5 (3.0) 10 (5.9) 3 (1.8) 16 (3.7) 17 (3.9) 46 (3.3) 53 (3.9)
Drug-related TEAE leading to discontinuation 3 (1.8) 8 (4.7) 2 (1.2) 8 (1.8) 11 (2.5) 27 (2.0) 35 (2.5)
SAE 1 (0.6) 1 (0.6) 1 (0.6) 12 (2.8) 7 (1.6) 29 (2.1) 29 (2.1)
Drug-related SAE NA NA NA 2 (0.5) 3 (0.7) 6 (0.4) 7 (0.5)
Common TEAEs by preferred term (reported by C3 % in any group)
Hypertension 0 3 (1.8) 3 (1.8) 37 (8.5) 49 (11.3) 105 (7.6) 103 (7.5)
Nasopharyngitis 12 (7.1) 3 (1.8) 4 (2.4) 14 (3.2) 15 (3.5) 35 (2.5) 54 (3.9)
Urinary tract infection 5 (3.0) 11 (6.5) 3 (1.8) 10 (2.3) 18 (4.2) 25 (1.8) 40 (2.9)
Headache 8 (4.7) 6 (3.6) 8 (4.7) 19 (4.4) 9 (2.1) 42 (3.0) 44 (3.2)
Dry mouth 3 (1.8) 5 (3.0) 3 (1.8) 9 (2.1) 8 (1.9) 29 (2.1) 23 (1.7)
Constipation 2 (1.2) 2 (1.2) 6 (3.6) 5 (1.2) 7 (1.6) 20 (1.4) 22 (1.6)
Influenza 4 (2.4) 5 (3.0) 7 (4.1) 7 (1.6) 3 (0.7) 19 (1.4) 19 (1.4)
Dizziness 1 (0.6) 1 (0.6) 6 (3.6) 2 (0.5) 10 (2.3) 12 (0.9) 13 (0.9)
Asthenia 0 1 (0.6) 6 (3.6) 0 0 2 (0.1) 1 (0.1)
Drug-related* TEAEs by preferred term (reported by C3 % in any group)
Hypertension 0 3 (1.8) 2 (1.2) 23 (5.3) 30 (6.9) 63 (4.6) 65 (4.7)
Headache 4 (2.4) 6 (3.6) 5 (3.0) 9 (2.1) 4 (0.9) 18 (1.3) 28 (2.0)
Dry mouth 3 (1.8) 5 (3.0) 3 (1.8) 8 (1.8) 7 (1.6) 22 (1.6) 13 (0.9)
Dizziness 1 (0.6) 0 6 (3.6) 1 (0.2) 7 (1.6) 8 (0.6) 10 (0.7)
SAF safety analysis set, TEAE treatment-emergent adverse event, SAE serious adverse event, NA not available
* Possible or probable, as assessed by the investigator, or records where relationship was missing
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at earlier timepoints (e.g., week 1 in the Phase III studies)
may also have helped determine whether more immediate
improvements are evident.
Conclusions
Mirabegron at doses of 25 and 50 mg once-daily over
12 weeks demonstrated superior efficacy versus placebo
for key symptoms of OAB. The efficacy of mirabegron
50 mg was evident as early as week—the first timepoint
measured in the Phase II study—for incontinence episodes,
and by week 4—the first measured timepoint in the pooled
Phase III studies—for the key OAB symptoms.
Mirabegron possesses the characteristics required to
ensure high rates of persistence in the long-term treatment
of OAB: an early onset of action and good tolerability
profile. Rapid onset of action provides patients with an
early perception of benefit from pharmacotherapy and may
help patients persist with treatment.
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